Key result
PCV-13 matches PCV-7 in immunogenicity and safety in children, but shows lower serotype 3 responses.
Why the study?
Additional serotypes included in PCV-13 compared to PCV-7 address important pneumococcal disease burdens, but immunogenicity and safety data in infants and toddlers needed synthesis.
Does PCV-13 provide similar immunogenicity and safety compared to PCV-7 in infants and toddlers?
Population
Infants and toddlers
Comparison
PCV-13 vs PCV-7
Design
Review of immunogenicity and safety studies
Authors
Loading...
PCV-13 targets high-burden serotypes 1 and 19A in low-income countries; leaves open real-world effectiveness and implementation questions.
Does PCV-13 provide similar immunogenicity and safety compared to PCV-7 in infants and toddlers?
PCV-13 demonstrates comparable immunogenicity and safety to PCV-7 in infants and children, providing broader serotype coverage.
Nunes et al. (2011) conducted a review in Pneumococcal disease. PCV-13 vs. PCV-7 was evaluated on Immunogenicity and safety. PCV-13 demonstrated a similar immunogenicity and safety profile to PCV-7 in infants and children, though an attenuated anamnestic response to serotype 3 was reported in 5 out of 14 studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: